Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2004 Dec;48(12):4864-8.

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Author information

1
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA.

Abstract

We observed a previously uncharacterized mutation in the protease substrate cleft, L23I, in 31 of 4,303 persons undergoing human immunodeficiency virus type 1 genotypic resistance testing. In combination with V82I, L23I was associated with a sevenfold reduction in nelfinavir susceptibility and a decrease in replication capacity. In combination with other drug resistance mutations, L23I was associated with multidrug resistance and a compensatory increase in replication capacity.

PMID:
15561868
PMCID:
PMC529213
DOI:
10.1128/AAC.48.12.4864-4868.2004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center